Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder

About this trial

Last updated 18 years ago

Study ID

A5091027

Status

Completed

Type

Interventional

Phase

Phase 3

Placebo

Accepting

18+ Years

All Sexes

Trial Timing

Ended 20 years ago

What is this trial about?

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients with genetically known disorder of extremely high cholesterol

What are the participation requirements?

Inclusion Criteria

* Diagnosis of Homozygous Familial Hypercholesterolemia

Exclusion Criteria

* Women who are pregnant or lactating, or planning to become pregnant.

* Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid

* Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors

* Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study